UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 AND 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the Month of September 2012
File No. 000-54598
Stellar Biotechnologies Inc.
(Name of Registrant)
332 E. Scott Street, Port Hueneme, CA 93041
(Address of principal executive offices)
Indicate by check mark whether the Registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
FORM 20-F __X__
FORM 40-F ______
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ___
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ___
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Form 6-K to be signed on its behalf by the undersigned, thereunto duly authorized.
Stellar Biotechnologies Inc.
(Registrant)
Dated: September 27, 2012 | By: /s/ "Darrell Brookstein" Darrell Brookstein Director |
Exhibits:
99.1
News Release dated September 26, 2012
Stellar Biotechnologies Presented at World Congress of Marine Biotechnology
PORT HUENEME, CA, (September 26, 2012) -- Stellar Biotechnologies, Inc. ("Stellar") (TSX-V: KLH) (PINKSHEETS: SBOTF) (Frankfurt: RBT) today announced that Frank Oakes, President and Chief Executive Officer of Stellar, presented at the 2nd Annual World Congress of Marine Biotechnology held September 20 – 23, 2012 in Dalian, China.
“We are the world leader in Keyhole Limpet Hemocyanin (KLH),” said Frank Oakes. “KLH is a critical material in immunology that is derived from a sole marine source, so we are intensely aware of the importance of the ocean’s fragile resources to pharmaceutical sciences.”
The World Congress of Marine Biotechnology brought together international scientists and industry leaders to discuss the global growth and latest developments in marine biotechnology. Mr. Oakes delivered a keynote talk titled “Marine Compounds in Immune Therapy; the Pathway to Commercialization” focusing on the deployment of KLH in immunology, one of the fastest growing pharmaceutical fields.
Frank Oakes is an international expert in the commercialization of marine-derived products, with specialization in sustainable aquaculture systems for biotechnology and seafood industries. Stellar Biotechnologies is championing KLH protection and development with support from the National Cancer Institute, the National Science Foundation, and the national Center for Research Resources.
For more information:
Visit Stellar Biotechnologies website and the KLH knowledge base KLH Site™.
About Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc. (TSX-V: KLH) (U.S. OTC: SBOTF) (Frankfurt: RBT) is the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH). KLH is an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. Potent, yet proven safe in humans, KLH operates as both a vital component for conjugate vaccines (targeting cancer, autoimmune, and infectious diseases) as well as an antigen for measuring immune status. Stellar Biotechnologies was founded to address the growing demand for renewable, commercial-scale supplies of high-quality, GMP-grade KLH. Stellar has developed leading practices, facilities and proprietary capabilities to address this need. To receive regular updates, enter email at bottom of http://stellarbiotechnologies.com/investors/news_releases/
Contacts:
Darrell Brookstein, Executive VP, Corporate Development & Finance dbrookstein@stellarbiotech.com
Frank Oakes, Chairman foakes@stellarbiotech.com
Main +1 (805) 488-2800
There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of these releases.